| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalaris Therapeutics, Inc. (KLRS) has 2 insiders with recent SEC Form 4 filings, including 0 buys and 13 sells. KLRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.50M | $7.73M | - | |
| CFO | 235.0K | $1.21M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | Hagen Brett R84 | Chief Accounting Officer | Sell | 907 | $8.97 | $8,135.16 | -32.0% | -73.0% | -36.8% | |
| Feb 21, 2025 | Sinha Vikas84 | See Remarks | Sell | 303 | $10.08 | $3,052.97 | -0.6% | -70.6% | +3.8% | |
| Feb 21, 2025 | Hagen Brett R84 | Chief Accounting Officer | Sell | 96 | $10.08 | $967.28 | -3.3% | -70.6% | +3.8% | |
| Feb 21, 2025 | Miller Edward82 | General Counsel | Sell | 106 | $10.08 | $1,068.03 | -1.6% | -70.6% | +3.8% | |
| Jan 23, 2025 | Miller Edward82 | General Counsel | Sell | 52 | $9.50 | $494.03 | -0.4% | -31.2% | -3.8% | |
| Jan 23, 2025 | Hagen Brett R84 | Chief Accounting Officer | Sell | 36 | $9.51 | $342.28 | -0.6% | -31.2% | -3.8% | |
| Jan 23, 2025 | Sinha Vikas84 | See Remarks | Sell | 129 | $9.50 | $1,225.86 | -0.1% | -31.2% | -3.8% | |
| Jan 10, 2025 | Miller Edward82 | General Counsel | Sell | 409 | $0.44 | $180.00 | -0.3% | -27.6% | -3.2% | |
| Jan 10, 2025 | Hagen Brett R84 | Chief Accounting Officer | Sell | 332 | $0.44 | $146.11 | -0.5% | -27.6% | -3.2% | |
| Jan 10, 2025 | Sinha Vikas84 | See Remarks | Sell | 979 | $0.44 | $430.86 | - | -27.6% | -3.2% |